Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KRAS mutant peptide-HLA complex (KRAS-mutant peptide-HLA)
- Target
- KRAS-mutant peptide-HLA
- Molecular classification
- Peptide-MHC Complex, Neoantigen, Cell Surface Receptor Ligand
01
Overview
The KRAS mutant peptide-HLA complex is a molecular structure formed when a peptide derived from a mutated KRAS protein (commonly found in various cancers) is presented on the cell surface by a human leukocyte antigen (HLA) class I molecule. This complex acts as a neoantigen, enabling recognition by T cell receptors (TCRs) or engineered antibodies, and serves as an important target for cancer immunotherapy. Common mutations include G12V and G12D, presented by HLAs such as HLA-A*11:01, HLA-A*03:01, and HLA-C*08:02.
- Other names
- KRAS neoantigenmutant KRAS-HLA complexKRAS pMHCKRAS-HLA complex
02
Mechanism of action
T cell mediated cytotoxicity
03
Biological functions
Antigen presentationT cell activationImmune responseTumor cell recognition
04
Disease associations
Cancer
05
Safety considerations
On-target, off-tumor toxicityCytokine release syndromeImmune-related adverse eventsLimited to patients with specific HLA alleles
06
Biomarkers
KRAS mutation statusHLA allele typeT cell infiltrationpMHC expression level
Beyond the preview
Go deeper on KRAS mutant peptide-HLA complex (KRAS-mutant peptide-HLA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KRAS mutant peptide-HLA complex (KRAS-mutant peptide-HLA).